Literature DB >> 11412225

Peyronie's disease-the Plymouth experience of extracorporeal shockwave treatment.

R Hamm1, E McLarty, J Ashdown, S Natale, A Dickinson.   

Abstract

OBJECTIVE: To describe our experience of the use of extracorporeal shockwave treatment (EST) for Peyronie's disease. Patients and methods The study included 28 patients (mean age 57 years, range 34-72) with stable Peyronie's disease who were treated with 3.9 (3-5) sessions of EST to the Peyronie's plaque. The patients' erectile function, pain and penile angle were assessed before and after treatment with EST.
RESULTS: Of the 28 patients, 20 felt that their erection improved after the procedure; 11 patients were able to recommence sexual intercourse and the index of erectile function increased in all but one patient. Conclusion EST produces a significant improvement in pain and penile angle, with no serious complications.

Entities:  

Mesh:

Year:  2001        PMID: 11412225     DOI: 10.1046/j.1464-410x.2001.02194.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

Review 1.  Update on medical management of Peyronie's disease.

Authors:  Ronny B W Tan; Premsant Sangkum; Gregory C Mitchell; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

Review 2.  Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain.

Authors:  Grzegorz Lukasz Fojecki; Stefan Tiessen; Palle Jörn Sloth Osther
Journal:  World J Urol       Date:  2016-04-23       Impact factor: 4.226

3.  Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience.

Authors:  Maher Abdessater; William Akakpo; Anthony Kanbar; Jérome Parra; Thomas Seisen; Emmanuel Chartier-Kastler; Sarah J Drouin; Morgan Roupret
Journal:  Asian J Androl       Date:  2022 Jan-Feb       Impact factor: 3.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.